Background. In subjects with heart failure, angiotensin converting enzyme inhibitors exhibit mild systemic antiadrenergic effects, as deduced from treatment-related lowering of systemic venous norepinephrine levels. The effects of angiotensin converting enzyme inhibitors on cardiac adrenergic drive in subjects with heart failure has not previously been investigated.
A ctivation of the adrenergic and renin-angiotensin systems in heart failure partially compensates for reduced intrinsic pump function by stabilizing central blood pressure and increasing contractility and heart rate, thereby improving perfusion of organs with autoregulatory control of flow.1-4 Although activation of these systems may initially be helpful, evidence suggests that their chronic activation may contribute to the pathophysiology of heart failure.1-6
The adrenergic and renin-angiotensin systems are closely interrelated. For example, renin release is under 3,1-adrenergic control, and angiotensin II may modulate adrenergic activity by facilitating synaptic release of norepinephrine. [8] [9] [10] [11] [12] Thus, a therapeutic intervention in heart failure that antagonizes one of these systems may also inhibit the other.
Vasodilator therapy with a variety of agents may improve clinical symptoms and hemodynamic function may have different effects on adrenergic activity. For example, administration of the direct-acting vasodilator hydralazine'5 or the calcium channel antagonist nifedi-pine19 increases central venous norepinephrine concentrations in subjects with heart failure. In contrast, the acute20 and chronic20,21 administration of angiotensin converting enzyme (ACE) inhibitors significantly lowers venous norepinephrine concentration in heart failure, indicating a fall in generalized adrenergic activity.
The ACE inhibitor-associated reduction in venous norepinephrine concentrations may be the result of improvements in hemodynamic function or secondary to mitigation of angiotensin II-facilitated norepinephrine release. The latter explanation is supported by the observation that ACE inhibitors decrease angiotensin II-facilitated norepinephrine release in animal models. [22] [23] [24] [25] The clinical significance of the antiadrenergic effects of ACE inhibition is not known, but it is possible that this property is an important component of the therapeutic efficacy of ACE inhibitors in heart failure. The purpose of this study was to measure the effects of ACE inhibition on cardiac adrenergic activity and myocardial 3-adrenergic receptors in subjects with heart failure.
The data indicate that chronic therapy with ACE inhib-itors is associated with a decrease in both systemic and cardiac adrenergic drive and an increase in myocardial 3-adrenergic receptor density but only in subjects with increased baseline adrenergic activity.
Methods

Study Objectives
This study was a prospective, double-blind, placebocontrolled, crossover study of the ACE inhibitor lisinopril in subjects with heart failure. The primary objective was to measure the effects of ACE inhibition on cardiac adrenergic drive and myocardial 3-adrenergic receptor density in heart failure. Secondary objectives were to relate changes in systemic and cardiac adrenergic activity induced by ACE inhibition to changes in cardiac function.
Subject Eligibility
Patients .18 years of age were eligible for study entry if they had symptomatic congestive heart failure and a left ventricular ejection fraction of <0.45. All patients were clinically stable and on constant doses of cardiac medications for at least 2 weeks before study entry. Patients with unstable angina; myocardial infarction within 3 months of study entry; systolic blood pressure <80 mm Hg; valvular stenosis; primary renal, hepatic, or hematologic disorders; and pregnant or nursing women were excluded from study entry. Permissible concomitant cardiac medications included diuretics, digitalis glycosides, class I antiarrhythmic drugs, nitrates, and anticoagulants. During the study period, diuretic dose was adjusted when clinically indicated, but doses of all other concomitant medications were unaltered. Excluded medications were f-adrenergic blockers, calcium channel blockers, other antihypertensive medications, and other vasodilators. All patients signed informed written consent forms approved by the Human Subjects Committee of the University of Utah Medical Center.
Study Design
The study consisted of three treatment periods: a 2-week baseline period and two 12-week double-blind periods. During the baseline period, all patients received a single-blind oral placebo once daily. Baseline noninvasive and invasive measurements were made during the second week of the baseline period. After completion of the baseline period, patients were randomly assigned to receive lisinopril or placebo. The initial oral dose of study medication was 5 mg/d. After 2 weeks, the dose was increased to 10 mg/d if the 5-mg dose was well tolerated. After 2 additional weeks, the dose was again increased to 20 mg/d if study medication was well tolerated. Subjects continued on the highest tolerated dose of medication for a total of 12 weeks of therapy, at which time the hemodynamic and adrenergic measurements were repeated. Subjects were then crossed over to receive the alternative therapy. The alternative medication was begun at the equivalent of 5 mg/d and titrated upward as in the first 12-week doubleblind treatment period. After 12 weeks of treatment on the second study medication, hemodynamic and adrenergic measurements were again repeated.
Clinical and Hemodynamic Measurements
Clinical and hemodynamic measurements were made during the baseline period and during the last week of the two double-blind treatment periods. During the baseline period, two modified Naughton exercise tolerance tests26 were performed, with measurement of maximal oxygen consumption by expired gas analysis with mass spectrometry.27 Dyspnea or fatigue was used as the end point to terminate exercise. All other reasons for termination of exercise excluded patients from further participation in the study. Patients were also excluded if maximal oxygen consumption varied by more than 20% between tests. The average exercise duration and maximal oxygen consumption were used for the baseline value. A single exercise tolerance test was performed at the end of both of the two double-blind treatment periods. Radionuclide ventriculography was performed at rest and during maximal supine bicycle exercise for measurement of left ventricular ejection fraction. Chest radiography, electrocardiography, and clinical laboratory tests, including a complete blood count with differential, platelet count, urinalysis, and multichannel chemistry profile, were also performed.
Cardiac catheterization was performed on the last day of each treatment period. Patients fasted overnight before catheterization. Diuretics were not administered on the day of the catheterization, but study medication was given 2 hours before catheterization. Patients received preoperative sedation with diazepam (10 mg PO). A 9F sheath was inserted percutaneously into the right internal jugular vein, and a 20-gauge catheter was inserted into the right femoral artery under local anesthesia. When technically possible, a 7F multipurpose catheter (MA-2, Argon Medical, Athens, Tex) was inserted into the coronary sinus via the right internal jugular sheath, and the catheter position was confirmed by contrast dye injection and blood gas measurement of the coronary sinus sample. Simultaneous coronary sinus and arterial blood samples followed by a right atrial blood sample were obtained for measurement of catecholamine concentration and placed into iced tubes containing ethyleneglycol-bis-(13-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA). Right ventricular endomyocardial biopsy specimens were obtained by previously described methods.28 Briefly, a 50-cm right ventricular bioptome was inserted through the right internal jugular sheath and was positioned against the right intraventricular septum under fluoroscopic guidance, and specimens were obtained. Four to six specimens (20 to 40 mg) were obtained for -3-adrenergic receptor analysis. A pulmonary artery catheter was then inserted, and systemic and pulmonic pressures were measured. Cardiac output was measured by the Fick method. Heart rate was determined by electrocardiographic telemetry. Derived hemodynamic measures were calculated according to standard formulas. Adrenergic Measurements
We have previously described in detail the technique of f8-adrenergic receptor density measurement in endomyocardial biopsy specimens. 29 Briefly, biopsy specimens were immediately placed in ice-cold 10-mmol/L Tris buffer, 1-1tmol/L EGTA buffer, pH 8.0, and grossly visible fibrous tissue was dissected free. The remaining sample was blotted dry and weighed. Crude membrane preparations were then made by homogenization, extraction of contractile proteins in 0.5-mol/L KCl, and multiple washes of a pellet from centrifugation at 50 000g. The radioligand [125Ijiodocyanopindolol (ICYP) was used for identifying /3-adrenergic receptors. Duplicate tubes containing seven increasing concentrations of ICYP with and without 10-6 mol/L (-)-propranolol were prepared. The assay was begun with the addition of membrane preparation for 120 minutes. ICYP bound to membranes was then trapped by vacuum filtration, with specific binding defined as total binding minus propranolol-displaceable binding. Maximum bound ICYP (B..) and the ICYP dissociation constant (Kd) were determined by a nonlinear leastsquares regression analysis of one form of the Michael- A 50-mL heparinized mixed venous blood sample was obtained for measurement of lymphocyte f3-adrenergic receptor density by a modification of a previously described technique. 32 Briefly, a Ficoll gradient was used for harvesting lymphocytes. Crude membrane preparations were then prepared by homogenization and multiple washes of a 50 000g pellet. The radioligand ICYP was used for identifying P-adrenergic receptors.
Duplicate tubes containing eight increasing concentrations of ICYP with and without 10-6 mol/L (-)-propranolol were prepared. The assay was begun with the addition of the membrane preparation and incubated for 90 minutes, followed by vacuum filtration. Binding parameters and protein measurements were determined as for myocardial membranes.
Plasma catecholamine concentrations of blood samples from right atrium, systemic artery, and coronary sinus were analyzed by a radioenzymatic method (CATa-Kit, Amersham, Chicago, Il1).33
Statistical Analysis
The values for noninvasive, invasive, and adrenergic variables before and after lisinopril and placebo treatment were compared with their respective baseline values with the paired Student's t test. Since the trial was a crossover design, the baseline values for the second study period (weeks 13 to 24) were the end-ofstudy values for period 1 (weeks 1 to 12). Because values for norepinephrine concentration were not normally distributed, the log transformation of norepinephrine concentration was used for paired analysis of these variables. To evaluate the effect of baseline adrenergic activity on the response of adrenergic indexes to lisinopril and placebo therapy, all subjects were divided by rank order into two subsets determined by coronary sinus norepinephrine concentration. Differences between coronary sinus norepinephrine subsets were evaluated with the unpaired Student's t test. Additionally, changes from baseline with lisinopril treatment were compared with changes from baseline with placebo treatment by Student's t test. All values are expressed as mean±SEM. Differences were considered significant when P<.05.
Results
Patient Characteristics
Although 20 subjects were enrolled into the study, serial coronary sinus sampling was technically possible in only 14 subjects. This report is based on the data from these 14 subjects. Entry characteristics are given in Table 1 . Subjects received a mean lisinopril dose of 16.4±1.3 mg/d (range, 5 to 20 mg/d) and a mean placebo dose of 17.5±1.4 mg/d (range, 5 to 20 mg/d). One patient required hospitalization for heart failure after his condition deteriorated when he was crossed over from lisinopril to placebo (determined after completion of the study). However, his condition improved with bed rest and intravenous diuretic therapy, blinded study medication was continued, and he completed the study. No other significant adverse events occurred during the study, and no significant changes were observed in any clinical laboratory tests.
Right ventricular endomyocardial biopsy was not technically possible in one subject because of a septal scar from an old inferior wall myocardial infarction. All other measurements were completed in all 14 subjects.
Response to Therapy
The responses of invasive, noninvasive, and adrenergic variables to therapy with lisinopril and placebo are given in Table 2 . With lisinopril treatment, systemic venous norepinephrine concentration tended to decrease, but this was not statistically significant. There was also a small but statistically significant decrease in lymphocyte Kd with lisinopril therapy. All other variables did not change with lisinopril therapy. Placebo therapy was associated with an increase in lymphocyte Kd. No other variable changed with placebo therapy, although a trend toward an increase in venous norepinephrine concentration was observed. By betweengroup analysis, the changes in lymphocyte Kd were statistically significant, but this is of uncertain relevance. There were no other significant differences in changes from baseline between lisinopril and placebo treatment.
To examine whether an "order effect" caused by the crossover nature of the trial design might have been present, we analyzed the response to lisinopril or placebo in the first and second periods of the study. With the exception of heart rate, baseline data for the second period (13 to 24 weeks) of the study did not differ from the first period (1 to 12 weeks). Heart rate decreased from 85.8±4.2 beats per minute to 75.3 beats per minute (P=.04) between the two baseline periods. This reduction in heart rate did not appear to be related to a change in the adrenergic drive or hemodynamic status, since coronary sinus norepinephrine (597±154 pg/mL, first baseline; 671±336 pg/mL, second baseline) and pulmonary wedge pressure (14.4±2.1 mm Hg, first baseline; 14.3±2.3 mm Hg, second baseline) did not change between the two baseline periods. Myocardial biopsy 8-receptor density tended to be higher (P=.08) on the second baseline (47.3 vs 32.6 fmol/mg). These changes (heart rate) or tendencies (biopsy receptor density) were observed in subjects randomized to either lisinopril or placebo in study period 1. Despite the lack of overall change in baseline data between study periods 1 and 2, there were differences in the response to lisinopril in the first vs the second study period. In the first study period, subjects treated with lisinopril exhibited an increased 8-receptor density (from 22±2 to 51±9 fmol/mg; P=.02), a decreased systemic venous norepinephrine (from 564±177 to 250±103 pg/mL; P=.02), and a trend toward a reduced coronary sinus norepinephrine (from 864±353 to 533±107 pg/mL; P=.08). In the second study period, there were no significant differences in the above parameters, but trends in the same direction as in study period 1 translated into no significant differences in the end-of-study value minus baseline values in the two periods. There were no significant differences in the placebo group change from baseline values in either study period. The reason for the difference in behavior of lisinopril-treated patients in study period 1 vs 2 was that, by chance, five of the seven subjects in study period 1 were in the high coronary sinus norepinephrine subset (see below), whereas in period 2, only two lisinopriltreated patients were in this category. As would be expected from the crossover design, this preponderance of subjects in the high coronary sinus norepinephrine subset appeared in the placebo group in the second study period (five in the second, two in the first period). However, since placebo had no effect on any adrenergic parameter, the changes in the placebo group did not differ between periods 1 and 2.
Response to Therapy of Subjects With "High" and "Low" Cardiac Adrenergic Activity Subjects were divided by rank order into two groups of equal number determined by coronary sinus norepinephrine. For lisinopril treatment, coronary sinus norepinephrine concentration ranged from 404 to 4964 pg/mL in the "high" subset (group A) and 71 to 339 pg/mL in the "low" subset (group B). Table 3 presents noninvasive and invasive measurements before and after lisinopril treatment for groups A and B. Subjects in group A tended to have a higher resting heart rate, higher right heart pressures, and lower cardiac index than group B subjects, but these differences were not significant. With lisinopril treatment, there were trends toward hemodynamic improvement in group A and an improvement in left ventricular ejection fraction in group B, but these changes were not significant. Figure   1 presents the changes in coronary sinus norepinephrine concentration and myocardial 13-receptor density for groups A and B. In group A subjects, treatment with lisinopril was associated with a significant fall in coronary sinus norepinephrine concentration and a significant increase in myocardial 3-receptor density. No changes occurred in group B. Lymphocyte (-receptor density did not change in either group. For placebo treatment, coronary sinus norepinephrine concentration ranged from 282 to 853 pg/mL in group A and 145 to 234 pg/mL in group B. Table 4 presents noninvasive and invasive measurements before and after placebo treatment for groups A and B. Subjects in group A tended to have higher right heart pressures than group B subjects. There were no changes in noninvasive, invasive, or adrenergic variables in either subset. However, as shown in Table 4 In group A, there were significant differences in the percent change from baseline for lisinopril vs placebo therapy for myocardial Bma.,, right atrial norepinephrine concentration, and coronary sinus norepinephrine concentration. In group B, there were no significant differences in change from baseline for lisinopril vs placebo therapy.
Discussion
Lisinopril, the lysine analogue of enalaprilat, is a long-acting ACE inhibitor.34 Oral administration of lisinopril inhibits the pressor response to exogenous angiotensin I, increases plasma renin activity, decreases plasma ACE activity, and decreases both plasma angiotensin II and aldosterone concentrations. 34, 35 In subjects with heart failure, oral administration of lisinopril results in increases in cardiac output and stroke volume, decreases in systemic vascular resistance and pulmonary wedge pressure, 35 and improvement in heart failure symptoms and exercise tolerance.36 Significant hemodynamic effects have been observed with doses of 10 mg/d or less, and the effects of a single dose may last 24 hours. [35] [36] [37] In this study, we did not observe any significant hemodynamic or exercise tolerance improvements with lisinopril therapy. Subjects with evidence for increased cardiac adrenergic activity (the "high" coronary sinus norepinephrine subset) tended to show hemodynamic improvement, but these changes were small and not statistically significant. However, other studies with lisinopril in heart failure using large sample sizes have shown improvement in hemodynamics35 and exercise performance. 36 In contrast to the minor hemodynamic effects of lisinopril in our study, subjects with increased cardiac adrenergic activity (group A) exhibited significant decreases in coronary sinus and systemic venous norepinephrine concentrations in response to lisinopril therapy but not in response to placebo. Additionally, the significant increase in myocardial /3-adrenergic receptor density in the high adrenergic drive subset was associated with the fall in coronary sinus and systemic venous norepinephrine concentrations in subjects treated with lisinopril. These changes were observed only in subjects with evidence for an increase in adrenergic drive at baseline and were not observed in subjects with normal baseline coronary sinus norepinephrine concentrations.
The data in this trial were analyzed by the degree of baseline adrenergic activation, since effects of ACE inhibition on adrenergic neurotransmission would be expected to be manifest only when adrenergic activity is increased. One possible explanation for the findings in this study is that the observed changes in norepinephrine concentration were an artifact of the division of subjects into subsets, resulting in a "regression toward the mean." If group A norepinephrine values were elevated because of the random scatter of baseline data and not because of an actual increase in baseline adrenergic activity, then it would be expected that these values would return toward the mean of the group on repeat measurement. However, it is unlikely that this explains our findings, since norepinephrine concentrations decreased in group A with lisinopril therapy but not with placebo therapy, during which norepinephrine concentration tended to increase. Thus, the observed changes in group A (the "high" norepinephrine subset) are likely to be an actual response to pharmacological intervention with lisinopril.
It has been demonstrated previously that the administration of ACE inhibitors in heart failure reduces systemic venous norepinephrine concentration. [19] [20] [21] In contrast, other vasodilators used for the treatment of heart failure increase systemic venous norepinephrine concentration. [11] [12] [13] [14] [15] [16] [17] [18] In this study, lisinopril therapy also tended to result in a generalized reduction in systemic venous norepinephrine concentration caused entirely by a lowering of adrenergic drive in the high norepinephrine subset. In addition, elevated coronary sinus norepinephrine concentrations in group A subjects were reduced by lisinopril therapy but not by placebo. These findings suggest that ACE inhibitors are capable of exerting a powerful antiadrenergic effect in subjects with elevated cardiac adrenergic activity. Such an effect, including upregulation of 3-adrenergic receptors, has recently been reported in an animal model.38 In humans with heart failure, the antiadrenergic effect is substantial when judged by lisinopril's effects on either coronary sinus norepinephrine levels or myocardial /3-receptor density. In fact, the observed upregulation of myocardial f8-adrenergic receptors was only slightly less than the upregulation observed in heart failure patients treated with chronic ,B-adrenergic blockade. 39 Although myocardial /3-adrenergic receptors increased with lisinopril therapy in group A, lymphocyte ,B-adrenergic receptors did not change. We have previously reported that in subjects with heart failure, the behavior of lymphocyte f32-adrenergic receptor density does not correlate with myocardial 813-adrenergic receptor density. 40 The findings in this study are further evidence that lymphocyte /3-receptor density cannot be used to evaluate the changes in the cardiac adrenergic pathway.
The design of the study does not permit determination of the mechanism by which lisinopril lowers cardiac adrenergic drive. One possible explanation for our observations is that drug therapy improved hemodynamic function, which resulted in a secondary reduction in reflexes responsible for increasing adrenergic drive. However, there were no significant changes in hemodynamic function in our patients with lisinopril therapy, even though large changes were observed in adrenergic indexes. Another possible explanation is that lisinoprilassociated reduction in angiotensin II levels eliminated the facilitory action of angiotensin II on adrenergic neurotransmission. Such a hypothesis is consistent with our observation that the adrenergic effect was observed only in subjects with elevated adrenergic activity. Against this explanation is the observation that infusions of angiotensin-II into human subjects without41 or with42 heart failure does not increase systemic adrenergic drive.41 However, the pressor effects of systemically infused angiotensin-II may activate arterial baroreflexes, causing systemic adrenergic activity to behave in a manner different from cardiac adrenergic neurotrans- and after (hatched bars) 12 weeks ofplacebo therapy for patients in the "high" (group A, n=7) and "low" (group B, n=7) coronary sinus norepinephrine subsets. No significant changes occurred with placebo therapy, although coronary sinus norepinephrine concentration tended to increase in the "high" subset. mission. Further studies will be necessary to elucidate the mechanism by which ACE inhibition lowers cardiac adrenergic drive in heart failure.
What is the clinical significance of the reduction in adrenergic drive with ACE inhibitors? Potentially, the antiadrenergic properties of ACE inhibitors are powerful enough to contribute to some of the beneficial effects of these agents in heart failure. For example, the improved exercise performance that has been observed with ACE inhibition in heart failure could be related to partial restoration of the myocardial 13-adrenergic receptor pathway through an increase in 3-adrenergic receptor density, just as has been reported with ,3-blocker therapy. 39 In addition, reducing resting adrenergic drive might have a cardioprotective effect3; this could be one of the reasons why ACE inhibitors are associated with improved survival in heart failure.43 This hypothesis is supported by findings of the CONSENSUS trial, in which improvement in survival was observed only in patients with increased indexes of neurohumoral activation. 44 In summary, ACE inhibition in subjects with heart failure and elevated cardiac adrenergic drive is associated with a decrease in coronary sinus and systemic venous plasma norepinephrine concentrations and an increase in myocardial P-adrenergic receptor density.
These changes are not observed with ACE inhibition in subjects without elevated cardiac adrenergic activity or with placebo therapy.
